Rationale for a trial of immunosuppressive therapy in acute schizophrenia (Q36716413)

15 August 2017

1 reference

title

Rationale for a trial of immunosuppressive therapy in acute schizophrenia (English)

1 reference

15 August 2017

0 references

Knight JG

1

1 reference

15 August 2017

Menkes DB

series ordinal

2

1 reference

15 August 2017

Highton J

series ordinal

3

1 reference

15 August 2017

Adams DD

series ordinal

4

1 reference

15 August 2017

language of work or name

English

0 references

publication date

23 January 2007

1 reference

15 August 2017

1 reference

15 August 2017

volume

12

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

424-431

1 reference

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Association of schizophrenia and autoimmune diseases: linkage of Danish national registers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Dopamine-receptor-stimulating autoantibodies: a possible cause of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Adult schizophrenia following prenatal exposure to an influenza epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Impact of substance abuse on the course and outcome of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Abnormal cerebrospinal fluid protein indices in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Multiple sclerosis--the plaque and its pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Increased numbers of CD5 B lymphocytes in schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Schizophrenia and HLA: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

The susceptibility to insulin-dependent diabetes mellitus is associated with C4 allotypes independently of the association with HLA-DQ alleles in HLA-DR3,4 heterozygotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Combined influences of Gm and HLA phenotypes upon multiple sclerosis susceptibility and severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

A susceptibility locus for multiple sclerosis is linked to the T cell receptor beta chain complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Molecular genetic studies of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Recent advances in the genetics of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Gene map of the extended human MHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Can autoimmune mechanisms account for the genetic predisposition to schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Short and long term immunosuppressive effects of clozapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Autoantibodies against brain septal region antigens specific to unmedicated schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Side effects of corticosteroid therapy. Psychiatric aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Double-blind evaluation of plasmapheresis in schizophrenic patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

High risk of schizophrenia and other mental disorders associated with chlamydial infections: hypothesis to combine drug treatment and adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Schizophrenia and other mental disorders require long-term adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

COX-2 inhibitors as adjunctive therapy in schizophrenia: rationale for use and evidence to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Maintenance therapy for lupus nephritis--something old, something new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Long-term corticosteroid treatment of myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Central nervous system lupus: a clinical approach to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

The blood-brain barrier in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Autoimmune diseases in the pedigrees of schizophrenic and control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

Absence of Rheumatoid Arthritis in Schizophrenia*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Juvenile onset diabetes and schizophrenia?

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

CD5 B lymphocytes in high-risk islet cell antibody-positive and newly diagnosed IDDM subjects

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Complement factor C4 in schizophrenia

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Complement allotyping explains MHC associations in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Intensive cortisone therapy in schizophrenia

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Use of large doses of cortisone in schizophrenia; clinical, physiological, and metabolic observations

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Central nervous system involvement in systemic lupus erythematosus: a new therapeutic approach with intrathecal dexamethasone and methotrexate

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Selective treatment of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038/SJ.MP.4001959

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4001959

1 reference

15 August 2017

1 reference